Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Common Equity (2020 - 2025)

HCW Biologics (HCWB) has disclosed Common Equity for 6 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 78.86% year-over-year to -$2.1 million, compared with a TTM value of -$2.1 million through Sep 2025, up 78.86%, and an annual FY2024 reading of -$6.8 million, down 150.29% over the prior year.
  • Common Equity was -$2.1 million for Q3 2025 at HCW Biologics, down from -$51972.0 in the prior quarter.
  • Across five years, Common Equity topped out at $54.0 million in Q3 2021 and bottomed at -$23.2 million in Q2 2021.
  • Average Common Equity over 5 years is $16.4 million, with a median of $13.5 million recorded in 2023.
  • The sharpest move saw Common Equity soared 406.21% in 2021, then plummeted 197.96% in 2025.
  • Year by year, Common Equity stood at $51.2 million in 2021, then decreased by 26.89% to $37.4 million in 2022, then crashed by 64.03% to $13.5 million in 2023, then tumbled by 150.29% to -$6.8 million in 2024, then skyrocketed by 68.88% to -$2.1 million in 2025.
  • Business Quant data shows Common Equity for HCWB at -$2.1 million in Q3 2025, -$51972.0 in Q2 2025, and -$8.6 million in Q1 2025.